FDA Grants Atia Vision Approval to Begin US Clinical Trial of OmniVu™ Lens System in Patients with Cataracts

CAMPBELL, Calif.--(BUSINESS WIRE)--Atia Vision, Inc., a Shifamed portfolio company, today announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a traditional feasibility clinical study of its OmniVu™ Lens System. This novel intraocular lens is designed to restore dynamic range of vision following cataract surgery, going beyond the capabilities of current presbyopia-correcting lenses. "This IDE approval marks a pivotal